Serono Rebif Blocked By Orphan Exclusivity, FDA Says, But Timing Is Unclear
Executive Summary
Serono has been informed by FDA that approval of its multiple sclerosis therapy Rebif is blocked by the orphan drug exclusivity of both Berlex' Betaseron and Biogen's Avonex, but has not been given a date for when that exclusivity will expire.
You may also be interested in...
Orphan Drug Status: Are Head-to-head Trials Needed To Show Superior Safety?
CSL Behring petitions FDA to revoke Wilate's orphan drug designation, but Octapharma counters that the effectiveness of its product's dual viral inactivation processes can be seen in post-market reporting.
Serono Rebif Approval Is First Orphan Drug Challenge Based On Efficacy
FDA's licensure of Serono's Rebif marks the first time the agency has overridden orphan drug exclusivity based on an efficacy endpoint, a March 7 1Office of Orphan Products Development memo outlining FDA's rationale for the approval states
Serono Rebif Approval Is First Orphan Drug Challenge Based On Efficacy
FDA's licensure of Serono's Rebif marks the first time the agency has overridden orphan drug exclusivity based on an efficacy endpoint, a March 7 1Office of Orphan Products Development memo outlining FDA's rationale for the approval states
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: